SI
SI
Advertise on SI

 Strategies & Market Trends | The New Economy and its Winners


Previous 10 | Next 10 
From: Doren7/7/2009 1:32:05 AM
   of 56281
 
Price Is EV’s ‘Elephant in the Room’

wired.com 

What the automakers couldn’t do, Cogan notes, is develop a battery pack that costs less than $20,000 to $30,000. That’s still the case today

-----

Exactly my sentiments. The battery is the thing and lithium is not going to cut it.

But they could easily squeeze more miles out of more aerodynamic designs and lighter materials.

Share Recommend | Keep | Reply | Mark as Last Read

From: Eric7/7/2009 2:09:11 AM
   of 56281
 
July 6, 2009, 10:39 am
Solar Stocks: Barclays Warns Q2 Results Could Disappoint
Posted by Eric Savitz

After a 70% rally off the March low, it might be time to get more cautious on the solar stocks.

At least, that is the advice this morning from Barclays Capital analyst Vishal Shah. He thinks the recent rally makes the stocks less attractive headed into Q2 earnings season, and advises taking a “selective approach.” In connection with the broader call, he cut price targets on Energy Conversion Devices (ENER), First Solar (FSLR), Suntech (STP) and Yingli (YGE).

The bottom line, Shah writes, is that he sees downside risk to shipments, margins and operating expense assumptions, which could drive valuations lower. He cites the following risk factors for the group:

•Germany concentration risk is increasing, with 50%-75% of shipments to Germany.
•Q3 is likely the peak for industry shipment as the German market is likely to be seasonally weak in Q4 and Q1, while new China and U.S. subsidy programs not likely to offset German market declines.
•Street consensus estimates modeling stable margins through second half and 2010 on lower poly prices; but he says rate of poly price declines are decelerating. He sees ASPs falling faster than cost reductions, resulting margin pressure starting in Q1 2010.
•Street 2010 estimates on average modeling 40% revenue growth on 110% EPS growth with relatively flat margins. He thinks Street estimates on costs are too low.
•Receivables risk is increasing, with more potential for customer insolvency.
•Recent rally fueled largely by multiple expansion
•Checks find some installers selling branded modules below purchase price to manage working capital. “Excess pricing pressure” has driven spot prices of FSLR module ASPS to the contract level.
•Inventory of low-cost modules remains high.
Here are a few details on his individual stock calls:

•Energy Conversion Devices: Target to $13, from $17. 2009 EPS estimate to 57 cents, from 58 cents. 2010 estimate to 12 cents, from 75 cents. “Although pipeline appears to be strong, continued large project pushouts and inability of customers to secure adequate financing is likely to impact shipments over the next few quarters,” he writes. Rating remains Equal Weight.
•First Solar: Target to $175, from $190. No estimate changes. He writes that channel inventory remains a problem due to the challenging financing environment and weak demand from German wholesale segment, but that issues on competitive pricing appears to be already reflected in the stock price. Rating stays Equal Weight.
•Suntech: Target to $16, from $17.50. Rating remains Equal weight. “Shipments are currently tracking down sequentially” for the fourth quarter, he writes, with the risk of steeper than expected ASP declines increasing.
•Yingli: Target to $16.50, from $18. Keeps Overweight rating. “Checks suggest module players are offering floating price contracts with 180-day price protection to gain share,” he writes. “Given the sharp decline in module prices since Q1, we believe risks of receivables write-down has increased significantly.”
In today’s trading:

•ENER Is down $1.24, or 8.2%, to $13.82.
•FSLR is down $6.82, or 4.4%, to $147.38.
•STP is down $1.41, or 7.7%, to $16.96.
•YGE is down $1.23, or 8.9%, to $12.63.

blogs.barrons.com 

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: Eric who wrote (50323)7/7/2009 9:39:34 AM
From: Bill Harmond   of 56281
 
07-Jul-09 09:15 ET In Play Oppenheimer discusses recent hospital survey : Oppenheimer says generally, 77% of respondents cut their capital spending budgets during their current fiscal year by a median 30%. For all respondents, FY09 budgets are expected to be down by a median 9%, while FY10 budgets are expected to be down even more—by a median 15%. For capital equipment, equipment replacement and ROI were the key factors for current capital expenditures. Firm generally expects 2Q to be worse sequentially, and would thus still avoid ISRG, VAR, HOLX, MR, and ARAY. For HCIT (Healthcare Information Technology), the results are more positive with the HITECH Act the primary driver, and it would seem that 1H09 could prove to be the trough for IT spending. The firm expects 2Q results for the major HCIT vendors to be in line with current expectations, particularly given a fairly low bar.

Share Recommend | Keep | Reply | Mark as Last Read

To: Lizzie Tudor who wrote (50321)7/7/2009 9:51:41 AM
From: Bill Harmond   of 56281
 
Bought some Childrens Place after Karen Finerman's recommendation last night on Fast Money.

cnbc.com 

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (2)

To: Bill Harmond who wrote (50325)7/7/2009 10:51:42 AM
From: bob zagorin   of 56281
 
a little info on eslr from a motley fool pieces..

"...... Evergreen Solar
Evergreen got an 11% boost on Thursday as a JPMorgan analyst upgraded the stock, citing the smooth operation of its Devens facility that could help it to meet the next demand upturn in solar. Some CAPS members think its new facility in Wuhan (China) will determine much of the company's future success, as it should help the company significantly improve production costs.

Evergreen Solar recently tapped the capital markets for $72.5 million, with some of the money set to help fund the China facility with a preliminary capacity of 100 megawatts. And it expects that the contracted use of Chinese firm Jiawei Solar, which has done work for Evergreen and SunPower (Nasdaq: SPWRA) before, will be a key factor in driving down cost to remain competitive with fast-moving peers. At this point, 92% of the 2,048 CAPS members rating Evergreen Solar are bullish and see it outperforming the broader market....."

Share Recommend | Keep | Reply | Mark as Last Read

From: bob zagorin7/7/2009 11:11:56 AM
   of 56281
 
FWIW JAGfn Rumor by JAGfn.com
(GERN) (PFE) Rumor that PFIZER INC(NYSE: PFE) will make a bid for Geron
Corporation (GERN) . Bid whispered to be cash in the $20 range.
News Provided by Acquire Media Corporation

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: bob zagorin who wrote (50327)7/7/2009 11:14:52 AM
From: bob zagorin   of 56281
 
recent news on gern starting with yesterday

Hot Stocks story about GERN
Geron Corporation announced the publication of data demonstrating that dendritic cells, or DCs, scalably manufactured from human embryonic stem cells, or hESCs, exhibit the normal functions of naturally occurring human DCs found in the bloodstream. These findings support the use of hESC-derived DCs in therapeutic vaccine applications for cancer and other diseases. Substituting standardized, off-the-shelf hESC-derived DCs for current approaches using DCs obtained from individual patients may result in more cost effective and reliable approaches to cancer immunotherapy.

July 1, 2009
07:49 EDT GERN

GE (GE) is moving further into stem cell research as Geron Corp. (GERN) has agreed to provide stem cells to GE's GE Healthcare for testing for the toxic effects of drug treatments, reports the Wall Street Journal. This is the first time a major company has said it's involved in a business venture in the controversial field of embryonic stem cells. The Obama administration has recently eased restrictions for that type of research.

June 30, 2009
10:03 EDT GERN

Geron Corp. (GERN) is rallying, after the company announced that it would partner with GE (GE) to develop and commercialize cellular products derived from human embryonic stem cells. The companies will use the embryonic stem cells to facilitate drug discovery and development, as well as toxicity screening. Under the deal, GE Healthcare has obtained an exclusive license to utilize Geron's intellectual property relating to enbryonic stem cells. After the companies announced their agreement, Merriman released a bullish note on Geron. The firm believes that Geron will receive royalties in the mid-single digits from GE, and the firm thinks that a "multitude" of products can be developed using stem cells. Moreover, Merriman predicts that Geron's stock will get another boost when the company begins a Phase I spinal cord study, which Merriman predicts will kick off next month. Merriman believes Geron will have several additional positive catalysts this year and it maintains a Buy rating on the stock. In early trading, Geron surged $1.40, or 20.93%, to $8.09.

Share Recommend | Keep | Reply | Mark as Last Read

To: bob zagorin who wrote (50311)7/7/2009 12:27:18 PM
From: David Bogdanoff   of 56281
 
ESLR gets touted quite a bit by several commentators on cnbc lately.
Bogtalk

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: David Bogdanoff who wrote (50329)7/7/2009 2:39:42 PM
From: bob zagorin   of 56281
 
too bad it hasn't moved the stock yet. i watch bloomberg because i can't handle the spin on cnbc. seems every time i turn it on i get a lecture on the virtues of capitalism and the evils of regulation..

Share Recommend | Keep | Reply | Mark as Last Read

From: bob zagorin7/7/2009 2:42:27 PM
   of 56281
 
vicl starting to move on this..

Vical Incorporated announced that the company will report tomorrow the interim efficacy results from the company's Phase 2 trial evaluating the potential for its TransVax therapeutic DNA vaccine to prevent cytomegalovirus reactivation and disease in immunosuppressed stem cell transplant recipients. CMV and organ transplant expert Mark D. Pescovitz, M.D., Professor of Surgery and Microbiology & Immunology, and Vice Chair of Research in Surgery at the Indiana University School of Medicine, is scheduled to join Vical management on the call.

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)
Previous 10 | Next 10 

Copyright © 1995-2013 Knight Sac Media. All rights reserved.